PubMed Health⌕ Search

Biomedical subjects

M Pike

Publications and source records attributed to M Pike.

43 records · Page 3Linked to original sources
PubMed1973

Immunotherapy for acute myelogenous leukaemia.

One hundred and seven untreated patients with acute myelogenous leukaemia (AML) were admitted to St Bartholomew's Hospital between 10 October 1970 and 31 January 1973. Before receiving drugs to induce remission they were allocated alternatively into 2 groups to decide their remission treatment-a group to receive chemotherapy alone and a group to receive the same chemotherapy with immunotherapy. The patients were then given induction chemotherapy and 45 of them attained complete remission. All patients in remission then received chemotherapy consisting of 5 days treatment every 28 days. Patients receiving immunotherapy were also given multiple weekly intradermal injections of irradiated stored AML cells and Glaxo B.C.G. using a Heaf gun. There were 19 patients in the group which received only chemotherapy during remission; 7 of these patients remain alive (median survival after attaining remission 303 days) and only 5 are still in their first remission (median remission length 188 days). Twenty-three patients were allocated to receive immunotherapy during remission in addition to chemotherapy and 16 remain alive (median 545 days) and 8 are in their first remission (median 312 days). The difference in survival of the two groups is significant with a P value of 0·003.

Adolescent↗
PubMedDate not supplied

Cancer near nuclear installations.

The OPCS report on cancer incidence and mortality in the vicinity of nuclear installations in England and Wales provides a mass of information that is so large that it should be possible to detect quite small changes in disease levels with considerable confidence. The data on cancer mortality are less subject to selective bias than the registration data on which incidence rates are based, and they provide the firmest grounds on which evidence of any effect can be obtained. These data show conclusively that there has been no general increase in cancer mortality in the vicinity of nuclear installations in a 22-year period beginning several years after the opening of the installations that have released the largest amounts of radionuclides to the environment. On the contrary, the mortality from cancer has tended to be lower in the LAAs in the vicinity of nuclear installations than in control LAAs selected for their presumed comparability with the former. This is unlikely to be due to a protective effect of ionizing radiation and suggests that, despite the efforts that were made to choose comparable control areas, there were non-installation differences between the populations relevant to the risk of dying from one or other type of cancer. Detailed examination of the few types of cancer that were relatively more common in the installation areas suggest that several of the differences were most likely to be due to chance, diagnostic artefacts or social factors rather than to any hazard specifically related to the installations. One disease provides a possible exception: namely, leukaemia in the age group 0-24 years. Two other diseases need further investigation, multiple myeloma and Hodgkin's disease in the older age group 25-74 years. The excess mortality rates recorded from these cancers were not large, and it has yet to be established that they are not due to general confounding by other environmental or socio-economic factors.

Age Factors↗
PubMedDate not supplied

Phase I trial of interferon-gamma (IFN-gamma) retroviral vector administered intratumorally to patients with metastatic melanoma.

BACKGROUND: Interferon-gamma (IFN-gamma) gene/retroviral vector cell vaccinations have generated protective responses from unmodified tumor cell challenges as well as a regression of established tumors in animal models. The purpose of this trial was to determine the feasibility and safety of a direct intratumoral injection of IFN-gamma retroviral vector in advanced melanoma patients. METHODS: This was a phase I study, in which 13 patients received a single daily injection of a retroviral vector with the IFN-gamma gene for 5 consecutive days (1.5 x 10(8) colony-forming units total dose); patients subsequently underwent resection of the injected lesion to confirm DNA transduction in situ. RESULTS: No toxicity related to the injected vector was observed. Replication competent retrovirus was not observed in any prepared samples (n = 65). IFN-gamma expression was confirmed in 3 of 10 harvested tumor samples; one was equivocal, and DNA transduction was unable to be confirmed by enzyme-linked immunospot assay in six samples. CONCLUSIONS: An injection of IFN-gamma gene/retroviral vector is well tolerated. DNA transduction was demonstrated in human subjects, confirming the feasibility of the direct injection approach for the gene therapy of solid tumors. Further trials to determine optimal schedule and potential efficacy are indicated.

Adult↗